← Back
NeuroTrials.ai
Neurology Clinical Trial Database

Vamorolone for Duchenne

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to <18-year-old boys with duchenne muscular dystrophy

Year of Publication: 2026

Authors: Lochmüller H, Gonorazky H, Nigro E, ..., Hoffman EP

Journal: Journal of Neurology

Citation: Lochmüller H, et al. Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to <18-year-old boys with duchenne muscular dystrophy. J Neurol. 2026;273(3):177.

Link: https://doi.org/10.1007/s00415-026-13711-6


Clinical Question

Is vamorolone safe and well tolerated in older (7- to <18-year-old) boys with DMD, including those switching from classic corticosteroids, and how does it affect growth, bone biomarkers, and adrenal function?

Bottom Line

Vamorolone demonstrated a consistent safety profile in 7- to <18-year-old boys with DMD with no negative effect on growth (and catch-up growth in previously CS-treated boys). Switching to 6 mg/kg/day rather than 2 mg/kg/day appeared to mitigate the risk of adrenal insufficiency when transitioning from classic corticosteroids.

Major Points

  • 34 boys aged 7- to <18 years (12 CS-untreated, 22 CS-treated) all completed the 12-week VBP15-006 study and continued into the EAP Canada expanded access protocol.
  • Most treatment-emergent adverse events were mild.
  • No negative effect on growth: CS-untreated participants maintained stable linear growth, while previously CS-treated participants exhibited catch-up growth consistent with serum bone biomarkers (median total vamorolone exposure 1.3 years CS-untreated vs 1.7 years CS-treated).
  • Some weight gain occurred, especially in CS-untreated participants receiving 6 mg/kg/day.
  • Dose-dependent adrenal suppression occurred in both groups; 2 individuals who switched from deflazacort to vamorolone 2 mg/kg/day developed generalized weakness consistent with adrenal insufficiency, and switching to 6 mg/kg/day appeared to mitigate this risk.
  • Vamorolone showed dose-dependent pharmacokinetics with rapid clearance and no accumulation.
  • No relevant efficacy changes were observed in CS-treated or CS-untreated groups at either dose (exploratory).

Design

Allocation: Sequential, non-randomized — first participants assigned to 2 mg/kg/day; once each age/CS-treatment group was fully recruited, subsequent participants assigned to 6 mg/kg/day

Analysis: Descriptive safety, tolerability, and pharmacokinetic analysis; EAP Canada results presented for pooled 2-6 mg/kg/day dose group

Analyzed: 34

Blinding: Open-label

Centers: 5

Countries: Canada

Follow-up Duration: 12 weeks core study, then ongoing EAP Canada (median total vamorolone exposure 1.3 years CS-untreated, 1.7 years CS-treated; EAP data cut-off May 2025)

Randomization:

Registration: ClinicalTrials.gov NCT05185622, NCT03863119 (first submitted 09-11-2021)

Sample Size: 34

Study Type: Phase II, non-randomized, multiple-cohort, open-label, multiple-dose study followed by expanded access protocol (EAP Canada)


Inclusion Criteria

  • Male individuals with DMD confirmed by genetic testing and/or dystrophin deficiency on muscle biopsy
  • Aged 7- to <18 years
  • Evidence of immunity to varicella zoster virus
  • CS-untreated (no oral CS or other oral immunosuppressive agents for at least 3 months prior to enrollment) OR previously treated with standard-of-care classic CS switching directly to vamorolone on day 1

Exclusion Criteria

  • Major renal or hepatic impairment
  • Diabetes mellitus
  • Immunosuppression
  • Severe behavioral or cognitive problems
  • Medical conditions that could compromise safety or study completion

Arms

FieldCS-untreated, vamorolone 2 mg/kg/dayCS-untreated, vamorolone 6 mg/kg/dayCS-treated (switch), vamorolone 2 mg/kg/dayCS-treated (switch), vamorolone 6 mg/kg/day
Duration12 weeks (then EAP Canada)12 weeks (then EAP Canada)12 weeks (then EAP Canada)12 weeks (then EAP Canada)
InterventionVamorolone 2 mg/kg/day for 12 weeks (no oral CS for ≥3 months prior)Vamorolone 6 mg/kg/day for 12 weeks (no oral CS for ≥3 months prior); max daily dose 300 mg for participants ≥50 kg after protocol amendmentDirect switch from standard-of-care classic CS (prednisone/deflazacort) to vamorolone 2 mg/kg/day on day 1 for 12 weeksDirect switch from standard-of-care classic CS (prednisone/deflazacort) to vamorolone 6 mg/kg/day on day 1 for 12 weeks
N0000

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Safety, tolerability, and pharmacokinetics of vamorolone (2 vs 6 mg/kg/day) over 12 weeks of treatment in 7- to <18-year-old boys with DMDPrimaryMost treatment-emergent adverse events mild; all 34 participants completed the study; dose-dependent PK with rapid clearance and no accumulation
Most treatment-emergent adverse events were mildSafety
Dose-dependent adrenal suppression in both CS-untreated and CS-treated participantsSafety
2 individuals who switched from deflazacort to vamorolone 2 mg/kg/day developed generalized weakness consistent with adrenal insufficiency; switching to 6 mg/kg/day appeared to mitigate adrenal insufficiency riskSafety
Some weight gain, especially in CS-untreated participants receiving 6 mg/kg/daySafety
No negative effect on growth; CS-untreated maintained stable linear growth and CS-treated showed catch-up growth consistent with serum bone biomarkersSafety

Subgroup Analysis

Outcomes assessed by prior CS status (untreated vs treated/switched) and by dose (2 vs 6 mg/kg/day). Adrenal insufficiency events occurred in the deflazacort-to-2 mg/kg/day switch subgroup; weight gain most notable in CS-untreated at 6 mg/kg/day; catch-up growth in previously CS-treated participants.


Criticisms

  • Non-randomized, open-label design with no concurrent control arm
  • Small sample size (34) with per-dose subgroups too small for definitive comparisons
  • Exploratory efficacy assessments only; EAP Canada not designed to assess effectiveness and used pooled, physician-discretion dosing
  • Industry-sponsored (Santhera), with several authors employed by the sponsor

Funding

Santhera

Based on: Vamorolone for Duchenne (Journal of Neurology, 2026)

Authors: Lochmüller H, Gonorazky H, Nigro E, ..., Hoffman EP

Citation: Lochmüller H, et al. Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to <18-year-old boys with duchenne muscular dystrophy. J Neurol. 2026;273(3):177.

Content summarized and formatted by NeuroTrials.ai.